Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EU won’t renew J&J, AstraZeneca vaccine contracts, report says

By Sean Whooley | April 14, 2021

COVID-19 therapies vaccines coronavirus

[Photo by Daniel Schludi on Unsplash]

Reports from Italy claim that the European Union Commission won’t renew COVID-19 vaccine contracts next year with AstraZeneca and Johnson & Johnson.

According to Reuters, Italian outlet La Stampa reported that sources from the Italian health ministry have said the commission does not want to pursue contract renewals with those two companies once those encompassing the current year expire, with Brussels reportedly emphasizing its focus on mRNA vaccines like those produced by Pfizer/BioNTech and Moderna.

The report quoted an EU Commission spokesperson as saying the commission is keeping all options open to prepare for the next stages of the pandemic, but it can’t comment on contractual matters.

Later on today, the EU Commission president stated that the EU was in talks with Pfizer and BioNTech over a new contract for 1.8 billion doses as well, Reuters reported.

News of the potential for Europe to avoid renewing contracts with J&J and AstraZeneca follows a number of issues surrounding both vaccines, as the EU still seeks clarification from J&J on its announced delays in vaccine deliveries to Europe, according to Reuters.

The companies have also faced questions over safety with their vaccines, with the European Medicines Agency (EMA) last week finding a link between AstraZeneca’s COVID-19 vaccine and rare reports of blood clots and the U.S. earlier this week pausing use of the J&J COVID-19 vaccine after six cases of rare blood clots, one of which resulted in a death.


Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: AstraZeneca, BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccines, Johnson & Johnson, Moderna, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Theravision_FDA Revised Carton
Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market
midatech pharma janssen johnson & Johnson
J&J expands it long-acting injectables partnership with Midatech
Evonik launches new Eudratec tech to boost solubility of oral small molecules
PharmaJet Stratis
PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50